Articles tagged with Drug Therapy
A Johns Hopkins-led study published in New England Journal of Medicine found that convalescent plasma from recovered COVID-19 patients can effectively treat outpatients, with a 54% reduced need for hospitalization. The therapy's effectiveness increases with earlier administration within five days after diagnosis.
Levi A. Garraway is being honored for his groundbreaking contributions to cancer research, including the identification of melanoma genes and development of precision oncology approaches. He has also championed parallel sequencing as a definitive approach to tumor genomic profiling, revolutionizing cancer treatment strategies.
Researchers at Penn Medicine have developed a new approach to alter immune cells for CAR T cell therapy in just 24 hours, cutting manufacturing time from nine to 14 days. This could make the therapy more cost-effective and accessible to more patients.
Researchers developed a method to identify aggressive early-stage lung cancers and target drugs to tumors likely to respond. They used genomics network models and identified signature genes associated with tumor invasiveness.
Researchers developed a novel drug to reduce airway mucus that exacerbates common lung diseases. The treatment works by blocking the secretion of mucins, which can block airways and cause life-threatening symptoms.
The FDA has approved a novel combination therapy of relatlimab and nivolumab for patients with metastatic or inoperable melanoma. The treatment significantly delayed cancer progression time compared to nivolumab alone. LAG-3 blockade reinvigorated T cell anti-tumor activity, establishing the pathway as the third immune checkpoint target.
Researchers at Indiana University School of Medicine found that niacin modulates microglia response to amyloid plaques in an Alzheimer's disease animal model. The study identifies a potential novel therapeutic target for the disease, which can be modulated by FDA-approved drugs.
Researchers report promising results from a phase 3 clinical trial of MDMA-assisted therapy for post-traumatic stress disorder (PTSD), with two-thirds of participants no longer meeting the diagnostic criteria. The therapy showed better effect sizes than selective serotonin reuptake inhibitors (SSRIs) and was equally effective in treatm...
A new study led by Kelly Monaghan at West Virginia University suggests that interrupting the immune response may improve multiple sclerosis outcomes. The researchers found that targeting a specific protein called CCL17 can prevent the disease from attacking the central nervous system, leading to milder symptoms and delayed paralysis.
Researchers have found that immune checkpoint inhibitors like pembrolizumab can slow disease progression in patients with high-grade meningiomas. The study showed that nearly half of all patients were alive and without evidence of disease progression for at least 6 months after treatment.
Researchers at UC Berkeley discover that Antabuse helps improve sight in mice with retinal degeneration by reducing hyperactive retinal cells. The treatment may one day lead to better therapies for humans with inherited diseases like retinitis pigmentosa.
Researchers from UCLA Health and Harvard Medical School propose a new approach to studying and applying psychedelic compounds to foster intentional changes in habits and behaviors, potentially leading to improved health and resilience.
Researchers at Weill Cornell Medicine found that certain Candida albicans yeast strains produce a potent toxin called candidalysin, which damages immune cells and triggers pro-inflammatory responses. The study suggests a possible way to personalize treatments for IBD patients by targeting these high-damaging strains.
Researchers have developed a monoclonal antibody called PRN100, which showed safe and encouraging results in treating Creutzfeldt-Jakob disease (CJD) in six patients. While the findings are preliminary and require further studies, they offer new prospects for this rare and fatal disease.
A study in rural Ethiopia found that community-based rehabilitation, supported by local health centers and medication, reduced symptoms and improved functioning for individuals with schizophrenia. Community-based rehabilitation workers also helped participants access healthcare services and support their families.
A new study reveals that intra-tumoral injections of a plant virus-based immunotherapy could lead to groundbreaking therapy for both canine and human inflammatory breast cancer patients. The treatment generated potent local and systemic anti-tumor immune responses, improving quality of life and survival in treated dogs.
Researchers at the University of South Australia have developed a new way to deliver chemotherapy drugs, using liposomal formulations that target tumors more effectively. This breakthrough could improve treatment outcomes for thousands of cancer patients, reducing side effects and improving quality of life.
Researchers found that four-month treatment is as effective as six months in non-severe TB cases, allowing for savings on screening and training healthcare workers. The study's results led to a change in the World Health Organisation's global guidelines, recommending a shorter treatment course for children with non-severe TB.
A study at Duke-NUS Medical School found that inhibiting IL-11 can reduce kidney damage, inflammation, and scarring in Alport syndrome mice. Combining this therapy with ACEi treatment increased lifespan by over 400%.
The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors approved funding for 12 new comparative clinical effectiveness research studies focusing on maternal health, autism, and urinary incontinence. These studies will improve healthcare delivery and health outcomes in real-world settings.
Scientists at the Max Planck Institute of Biochemistry have discovered a new subtype of acute myeloid leukemia (AML) characterized by high amounts of mitochondrial proteins and altered mitochondrial metabolism. This subtype, called Mito-AML, shows clinical resistance to chemotherapy and can be effectively combated with inhibitors again...
Researchers found that verapamil treatment delayed disease progression, lowered insulin requirements, and preserved some beta cell function in patients with Type 1 diabetes. The study used proteomics analysis and RNA sequencing to examine changes in circulating proteins in response to verapamil treatment.
Researchers at the University of Pennsylvania have identified a key factor in T-cell leukemia disease relapse - genome refolding. The study found that cancer cells adapt to targeted therapy by changing the folding of their genome, driven by transcription factor repositioning.
Researchers found that Neem bark components target a wide range of viral proteins, suggesting its potential as an antiviral agent against emerging coronavirus variants. The study showed the bark extract was effective in reducing virus replication and spread in SARS-CoV-2 human lung cells.
A new study found that traditional Chinese medicine Shengmai Yin increases the sensitivity of cancer cells to radiation, reducing radioresistance. By altering DNA methylation status, SMY enhances the efficacy of radiation therapy and reduces side effects.
Researchers at UVA Cancer Center have made a groundbreaking discovery about the EP300 gene and its role in small-cell lung cancer. The study found that the gene makes a protein with properties that can both foster and prevent tumor formation, providing a new potential target for treatment.
A new study found that cashew stem bark extract inhibits abnormal gut motility associated with diarrhea, revealing a potential low-cost remedy for treating and managing the condition. The extract's mechanism of action involves blocking muscarinic acetylcholine receptors responsible for gastrointestinal motility.
Researchers from Tel Aviv University found that hyperbaric oxygen therapy (HBOT) relieves PTSD symptoms in treatment-resistant veterans, improving brain function and microstructure. The breakthrough study provides new hope for PTSD sufferers, offering an objective diagnostic tool and potential long-term improvements.
The AAN has issued an evidence-in-focus article on aducanumab, a treatment for early changes in the brain associated with Alzheimer's disease. The article notes that while aducanumab reduces amyloid plaques, its effects on symptoms and side effects are unclear.
Researchers have identified a key brain protein to target for new customized drug therapies treating adverse symptoms of developmental disorder subtypes. The study found that mutations in ARHGEF9 lead to intellectual disability through impaired α2 subunit function, which is a central hub for many neurological symptoms.
A new study from the University of Copenhagen has made significant breakthroughs in treating Parkinson's disease by targeting specific neurons in the brainstem. By stimulating excitatory neurons in the caudal area of the pedunculopontine nucleus, researchers were able to restore normal walking function in mice with Parkinson's symptoms.
Researchers at UC San Diego have made a groundbreaking discovery about the role of fibroblasts, or fat cells, in controlling bacteria and developing acne. These findings could lead to more targeted treatment options for acne, which affects up to 50 million Americans each year.
Researchers at the University of Toronto have identified hundreds of new proteins associated with cystic fibrosis, including those that interact with the CFTR protein. These discoveries may shed light on why some patients respond better than others to current therapies.
A small study found statistically significant improvements in various symptoms, including fatigue and chest discomfort, after EECP therapy in long COVID patients. Researchers believe this is the most plausible explanation for the benefits derived from EECP and its link to long COVID.
Researchers at NTU Singapore have developed a new method to generate sulphur pharmacophores, which are crucial for drug discovery. The method uses a catalyst called pentanidium and can produce multiple variations of pharmacophores, making the process more efficient and fruitful.
A new class of compounds improves insulin secretion and sensitivity, lowering blood sugar levels and reducing liver fat buildup in mice with diabetes. The study's findings offer hope for developing new treatments for cardiovascular disease and metabolic syndrome.
Researchers at Lancaster University have identified a genetic change that impacts insulin signaling and glucose metabolism in the brain, which may lead to effective drug treatments for autism. The study found that individuals with a specific DNA deletion are more likely to develop neurodevelopmental disorders, including autism.
Researchers have developed a new therapeutic approach to block mutated RAS proteins, which are frequently found in cancers. The method, using small molecules, has the potential to work with multiple mutant forms of RAS in various types of cancers, including pancreatic, lung, and colorectal cancers.
Pulmonary lymphangioleiomyomatosis (LAM) is a rare cancer affecting up to 1 in 1 million women worldwide, characterized by uncontrolled tumor cell growth. Researchers aim to identify new therapeutic targets using extracellular vesicles, with the goal of developing new therapies for LAM patients.
Researchers at Johns Hopkins Medicine found that certain stem cells have built-in tracers made of sugars that can track their movement in living tissues. The discovery could streamline and advance restorative research for diseases of the brain.
A recent study published in Developmental Cell reveals that Kras mutation causes chromatin rearrangement, leading to stem-like cell regeneration and tumor onset. The team discovered a protein complex called AP-1 as the mediator of this process, which can be targeted with small-molecule drugs.
A groundbreaking genome-wide association study identified 123 genetic regions linked to migraine risk, including two specific genes targeted by recently developed drugs. The study provides insight into the biological basis of migraine and its subtypes, paving the way for new treatments.
A study led by Clemson University geneticist Allison Hickman has identified 11 high-priority genes associated with uterine cancer. These genes are potential targets for drug therapies, offering new hope for effective treatment options.
A study led by RCSI researchers found that almost half of tumours with metastatic breast cancer in the brain have changes in DNA repair pathways, making them vulnerable to PARP inhibitor drugs. This discovery opens up potential novel treatment strategies for patients with limited targeted therapy options.
A recent University at Buffalo-led study found that nearly 1 in 7 COVID patients in ICU experienced severe bleeding when given full-dose blood thinners. The research compared the safety and effectiveness of two blood clot treatment strategies, finding that a smaller dose was equally effective but carried less bleeding risk.
Researchers report successful treatment of two young infants with PROS using breast cancer drug alpelisib, inducing rapid and significant clinical improvement in symptoms. The treatment was well-tolerated and showed promising results, supporting the use of low-dose alpelisib in these patients.
A new study by WVU researcher William Walker found that the blood-brain barrier is dynamic and more receptive to chemotherapy at night. This could lead to better treatment outcomes for patients with brain metastasis.
Researchers have identified two new compounds that can inhibit the replication of human herpesviruses by targeting specific enzymes. This breakthrough offers new opportunities for developing agents against herpesviruses, which are currently difficult to treat effectively.
A phase 3 clinical trial is underway to test the safety and efficacy of jacifusen, an experimental drug that lowered levels of toxic protein FUS in a patient with juvenile ALS. The trial aims to determine if the drug can slow disease progression in symptomatic patients.
Scientists have identified natural nano-bubbles containing the ACE2 protein in COVID-19 patients' blood, which can block infection from broad strains of SARS-CoV-2 virus. These nano bubbles serve as a decoy to lure the virus away from cells, preventing infection.
Researchers developed a gene therapy called Targeted Augmentation of Nuclear Gene Output (TANGO), which boosts SCN1A protein production in brain cells. The treatment restored normal cell function and reduced seizures in lab mice with Dravet syndrome, offering hope for the first direct treatment of the fundamental cause.
Researchers found that a third of patients with wet age-related macular degeneration can safely stop eye injection therapy without further vision loss. Patients who stopped treatment showed better visual acuity, gain of vision, and less fluid in their retina compared to those requiring continued injections.
A mathematical model developed by researchers at Massachusetts General Hospital has identified biological markers that can predict treatment responses in COVID-19 patients. The model reveals differences in patient characteristics and response to therapy, enabling clinicians to provide optimal care for diverse patients.
The Cardiovascular Research Foundation (CRF) will host THT 2022 from February 1-2, 2022. The conference features new and emerging treatments for heart failure, including transcatheter approaches and innovative monitoring strategies.
A new study found that oral bisphosphonates risedronate and alendronate equally protect against hip fractures during a 2-year drug holiday. However, the risk increases slightly for those taking a break from risedronate.
Researchers at Penn Medicine have discovered a new method to prevent the body's proteins from attacking treatment-carrying nanoparticles, allowing for more effective delivery of therapies. By coating nanoparticles with natural suppressors of complement activation, such as Factor I, the team has shown improved protection against immune ...
Researchers developed a color-coded test that quickly signals whether medical nanoparticles deliver their cargo into target cells. The tool, tested in mouse cells and living mice, assesses nanoparticle formulations on their ability to escape cellular defenses and reach the cell's interior.
Researchers discovered that aberrant splicing of CD22 mRNA leads to decreased protein expression in pediatric B-lymphoblastic leukemia cells. This results in resistance to CD22-directed immunotherapies, making it challenging for oncologists to identify patients who may not respond to these treatments.
Researchers at Penn Medicine have developed a structural blueprint for nanoparticles that can target and deliver treatment to white blood cells, such as neutrophils, that contribute to acute lung inflammation. The findings represent a significant step in understanding the condition and function of the immune system.
A new study published in the Canadian Journal of Cardiology found that frail patients with atrial fibrillation are under-prescribed for direct oral anticoagulants (DOACs), a safer alternative to traditional warfarin treatment. Despite needing DOACs most, these patients are less likely to receive them than non-frail patients.